Chemotherapy Toxicity in BRCA Mutation Carriers Undergoing First-Line Platinum-Based Chemotherapy

Abstract excerpt

Abstract Objective BRCA mutations are the most frequent mutations causing homologous recombination defects in epithelial ovarian cancers (EOC). Germline mutation carriers are heterozygous for the mutation and harbor one defective allele in all cells. This has been hypothesized to cause increased susceptibility to DNA damage in healthy cells as well as neoplastic ones. Our objective was to assess...

Topics

Join the communities discussing this publication.

• BRCA gene mutations in cancer
• Ovarian cancer diagnosis and treatment
• PARP inhibition in cancer therapy